Our findings further clarify the key effect of nucleus PLSCR1 on leukemia differentiation therapy and suggest the mechanism of wogonoside’s anti-leukemic activity, supporting the potential of developing wogonoside as a novel therapeutic agent for clinical treatment of AML patients. This evidence concerns the gene PLSCR1 and leukemia.